The IRS today released an advance version of Notice 2020-15 as guidance allowing individual taxpayers with high-deductible health plans to receive testing and treatment related to the novel coronavirus (COVID-19) without jeopardizing the status of these health plans.
Notice 2020-15 [PDF 38 KB] provides guidance for individuals with a high-deductible health plan (HDHP) under section 223(c)(2)(A), and HDHPs that cover the cost of testing and treatment related to COVID-19. The notice also clarifies that an individual covered by the HDHP will not be disqualified from being an eligible individual under section 223(c)(1) who may make tax-favored contributions to a health savings account (HSA).
As further explained in a related IRS release—IR-2020-54—health plans that otherwise qualify as HDHPs will not lose that status merely because they cover the cost of testing for or treatment of COVID-19 before plan deductibles have been met. As the IRS noted, any vaccination costs continue to count as preventive care and can be paid for by an HDHP.
Today’s notice applies only to HSA-eligible high-deductible health plans. The IRS release directs employees and other taxpayers in any other type of health plan with questions about their own plan and its coverage to contact their health plan.
The KPMG logo and name are trademarks of KPMG International. KPMG International is a Swiss cooperative that serves as a coordinating entity for a network of independent member firms. KPMG International provides no audit or other client services. Such services are provided solely by member firms in their respective geographic areas. KPMG International and its member firms are legally distinct and separate entities. They are not and nothing contained herein shall be construed to place these entities in the relationship of parents, subsidiaries, agents, partners, or joint venturers. No member firm has any authority (actual, apparent, implied or otherwise) to obligate or bind KPMG International or any member firm in any manner whatsoever. The information contained in herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 4366, 1801 K Street NW, Washington, DC 20006.